Biopharma · FDA Approvals · Stock

JSPR Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to bl…

Assets on file: vensobafusp alfa

Catalyst calendar

Dated catalysts for JSPR, including recently decided ones.

Recent first-hand events

Every first-hand event for JSPR, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 9, 2026
03:24 PM
JSPRJasper Therapeutics, Inc.

vensobafusp alfa · NCT05504187 registry update

status: NOT_YET_RECRUITING → WITHDRAWN; enrollment: 24 → 0; why_stopped: → Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns

Trial registry changeClinicalTrials.govOpen record
Nov 2, 2026
03:21 PM
JSPRJasper Therapeutics, Inc.

vensobafusp alfa · NCT05476887 registry update

status: ACTIVE_NOT_RECRUITING → UNKNOWN

Trial registry changeClinicalTrials.govOpen record1 update
Oct 15, 2026
12:00 PM
JSPRJasper Therapeutics, Inc.

Jasper Therapeutics Completes IgAN Cohort Enrollment in Phase 2 Basket Study of Vensobafusp Alfa (KP104)

Jasper completed enrollment of 18 patients in Stage 1 of its Phase 2 renal basket study evaluating vensobafusp alfa in IgA nephropathy across three dosing cohorts. Initial interim data from the IgAN cohort is now expected by year-end 2026. The company also announced an expansion cohort in FSGS patients with first dosing anticipated in Q1 2027.

Trial registry changeSEC 8-K
Sep 30, 2026
12:00 PM
JSPRJasper Therapeutics, Inc.

Jasper Therapeutics completes enrollment in Phase 2 renal basket study of vensobafusp alfa in IgAN

This earnings release recaps completion of enrollment in the first cohort of the Phase 2 renal basket study of vensobafusp alfa (KP104) in IgA nephropathy patients. The company plans to report interim data in Q4 2026 and updated data in Q1 2027. It also notes commencement of enrollment in the IC-MPGN cohort and opening of an FSGS expansion cohort with first dosing expected in Q1 2027.

Trial registry changeSEC 8-KOpen record

Peers by market cap

Companies in the same sector closest to JSPR in market value.

JSPR FDA Calendar & Catalysts — Jasper Therapeutics | Biopharma · FDA Approvals | SimianX AI